# A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

> **NCT02980731** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 210 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02980731
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-13
- **Primary completion:** 2021-12-29
- **Final completion:** 2021-12-29
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980731, "A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02980731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*